Data from Pharmawand - Curated by Toby Galbraith - Date added 19 April 2017

Circassia Pharmaceuticals plc announces top-line results from its investigational house dust mite allergy immunotherapy phase IIb field study. In the study, both the active treatment and placebo greatly reduced subjects’ allergy symptoms and rescue medication use. As a result, the treatment did not show a significant effect compared with placebo and the study did not meet its primary endpoint. The results show the immunotherapy was well tolerated with a highly favourable safety profile.

Steve Harris, Circassia’s Chief Executive, said: “We are naturally disappointed by this outcome, which is in line with our cat allergy phase III study where there was also a very marked placebo effect. Although subjects receiving the immunotherapies in both these studies had greatly improved allergy symptoms, the strong placebo effect made it highly challenging to achieve the studies’ endpoints.

Comment: Following the receipt of disappointing cat allergy phase III results in June last year, Circassia halted significant new investment in its allergy portfolio while awaiting the outcome of its house dust mite field study. Following these new results, Circassia will make no further investment in its allergy programmes.


You will need to login, to leave a comment. is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Spontaneous Urticaria (CSU)

Use our patient case studies to discover how experts diagnose and treat chronic spontaneous urticaria

Visit Chronic Spontaneous Urticaria (CSU)


See information on best practice in solid organ transplantation, and expert discussions on related hot topics.

Visit Transplantation

Related Content